Ecolab Inc. vs Tilray Brands Inc — how do they compare? Ecolab Inc. trades at $282.18 (market cap $78.97B), while Tilray Brands Inc trades at $3.53 (market cap $530.54M). The key difference: Ecolab Inc. is far larger — about 148.8× Tilray Brands Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Tilray Brands Inc for 31 Days on average.
| ECL | TLRY | |
|---|---|---|
Market Cap | $78.97B | $530.54M |
Volume | 974,947 | 9,099,075 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $21.00 |
52-Week Low | $245.73 | $3.57 |
Typical Hold Time | 90 Days | 31 Days |
Enterprise Value | $87.75B | $684.46M |
Dividend Yield | 1.04% | — |
Signals from Pluang's Aura AI — not financial advice
ECL trades at $282.21, up 1.48% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $16.08B, net income of $2.08B, and a 12.57% net margin. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook is positive given earnings beats, dividend reliability, and strategic expansions like the CoolIT deal, though rising debt and cost pressures pose risks. With a consensus price target of $326.38 implying 16% upside, ECL offers growth potential but requires monitoring of leverage and execution.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →